2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?
Eur Heart J Cardiovasc Pharmacother
.
2023 Nov 2;9(7):595-596.
doi: 10.1093/ehjcvp/pvad065.
Authors
Mattia Galli
1
,
Felicita Andreotti
2
3
,
Pierre Sabouret
4
,
Felice Gragnano
5
6
Affiliations
1
Maria Cecilia Hospital, GVM Care & Research, 48033 Cotignola, Italy.
2
Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
3
Catholic University Medical School, 00168 Rome, Italy.
4
ACTION Study Group, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Sorbonne Université, 75013 Paris, France.
5
Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 81055 Caserta, Italy.
6
Division of Clinical Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", 81100 Caserta, Italy.
PMID:
37738449
DOI:
10.1093/ehjcvp/pvad065
No abstract available
MeSH terms
Acute Coronary Syndrome* / drug therapy
Fibrinolytic Agents* / therapeutic use
Humans
Platelet Aggregation Inhibitors
Substances
Fibrinolytic Agents
Platelet Aggregation Inhibitors